Tandem Diabetes Care Inc
(FRA:TD5A)
€
29.8
0.92 (3.19%)
Market Cap: 1.99 Bil
Enterprise Value: 2.02 Bil
PE Ratio: 0
PB Ratio: 9.19
GF Score: 78/100 Tandem Diabetes Care Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023 / 12:40PM GMT
Release Date Price:
€35.23
(-5.35%)
Steven Michael Lichtman
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst
Good morning, everyone. I'm Steve Lichtman, medical devices analyst at Oppenheimer, and welcome to the Oppenheimer 33rd Annual Healthcare Conference. Up next for us, very happy to have Tandem Diabetes. With us this morning is CEO, John Sheridan; and CFO, Leigh Vosseller. We're going to do this in a fireside format. So, if you have any questions, please just enter them into the chat box on the webcast, and I will make sure to get them over to management. With that, John and Leigh good morning, and thank you for joining us.
John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director
Hi Steve. It's nice to be here.
Questions & Answers
Steven Michael Lichtman
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst
I thought first, we'll start on -- the latest news relative to Abbott's approval for integration with Control-IQ. Maybe if you could just update us on the timeline there?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot